Here’s what you should know:
1. Pfizer can launch its Humira biosimilar in the U.S. on Nov. 20, 2023. In Europe, Pfizer can launch as soon as it receives European Medicines Agency approval.
2. Pfizer will pay royalties to AbbVie after the launch.
3. If other Humira biosimilars launch, Pfizer will not be able to accelerate its launch. AbbVie has similar deals with other pharmaceutical companies.
4. Humira is AbbVie’s flagship product. The drug accounts for more than 60 percent of the company’s total sales. AbbVie believes Humira will approach $21 billion in sales in 2020.
5. By reaching the deal with Pfizer, AbbVie will have time to prepare new drug products before Humira biosimilars launch.
More articles on supply chain:
Ho, ho, ho & a helping hand — Arcadia Energetics 4-H club donates toys to St. Anthony’s patients
Bitten by a cow? The ICD-10 code for cattle attacks & 14 other wacky codes
St. James Hospital opens new medical office building with GI services — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.